Gilead and Lakefront close Ouro Medicines deal for $1.675bn
Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines, paying $1,675 million upfront with up to $500 million in contingent milestone payments.
The deal centres on gamgertamig (OM336), a clinical-stage BCMAxCD3 bispecific T cell engager designed to drive deep depletion of plasma cells and B cells following a short course of subcutaneous dosing, with the aim of inducing durable immune reset rather than chronic disease suppression.
The asset is being positioned by the two companies as potentially first-in-class and best-in-class in autoantibody-mediated orphan diseases, specifically autoimmune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP). The US FDA has granted gamgertamig both Fast Track and Orphan Drug Designation for both indications. The programme is currently in Phase 2 studies and the companies say registrational-stage trials could begin as early as 2027.
Deal structure and responsibilities
The upfront payment is split equally between Gilead and Lakefront, subject to customary adjustments, as are the contingent milestones. Lakefront has absorbed substantially all of Ouro's team and operational assets and will be responsible for running ongoing and future Phase 1/2 studies of gamgertamig. Gilead takes the lead on registrational and later-stage development and retains sole worldwide commercialisation rights outside territories controlled by Keymed Biosciences — the Chinese company from which gamgertamig was originally in-licensed, and which holds Greater China rights.
Lakefront will receive tiered royalties of 20–23% on Gilead's net sales of gamgertamig, a relatively generous royalty band that reflects the company's contribution to early-stage clinical execution. Lakefront has also in-licensed three additional preclinical autoimmune programmes from the Ouro portfolio, with Gilead holding an opt-in right to a 50/50 profit split post-clinical proof-of-concept at $75 million per programme.
The transaction also modifies an earlier Option, Licence and Collaboration Agreement between the two companies dating from 2019, giving Lakefront the freedom to deploy at least $500 million of its cash independently — including up to $150 million for share buybacks. Lakefront's year-end 2026 cash balance is expected to sit at approximately €2 billion.
Market context and competitive landscape
The T cell engager modality has attracted substantial industry investment in oncology, but its application to autoimmune disease remains earlier-stage and less crowded. The mechanistic rationale — using a CD3-engaging bispecific to redirect T cells against BCMA-expressing plasma cells — is analogous to the approach taken by approved myeloma agents such as teclistamab, but the therapeutic goal in autoimmunity is disease remission rather than tumour clearance, which brings a different tolerability calculus.
Gilead's broader ambition to move inflammation treatment "from chronic disease management toward durable immune reset" reflects a wider industry thesis that is also being pursued through CAR-T approaches by groups including Kyverna Therapeutics and Cabaletta Bio, as well as by Bristol Myers Squibb with its CD19-targeting programmes. The FDA's Orphan Drug Designation pathway provides an accelerated route for AIHA and ITP, both of which have limited approved options and relatively small but underserved patient populations.
For Lakefront — formerly Galapagos, which rebranded following a strategic restructuring — gamgertamig represents the centrepiece of a reconstituted pipeline built on deal-making rather than internal discovery. The company's considerable balance sheet and the royalty structure agreed with Gilead give it a commercially credible path to revenue without carrying full commercialisation costs, though clinical and regulatory execution risk ahead of the 2027 registrational-study target remains the key variable for investors to monitor.